指南与共识肝病

ELITA关于直接抗病毒药物在肝移植候选者及受者中应用的共识声明

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.
指南 / 共识 · J Hepatol · 2017-03-18

该共识声明由ELITA制定,针对丙型肝炎病毒(HCV)肝移植候选者和受者使用直接抗病毒药物(DAA)的若干未充分解决的问题提供共识建议,涵盖移植前治疗以预防移植物再感染、部分候选者临床改善后可剔除等待名单、移植后治疗时机选择,以及DAA与免疫抑制剂等药物的相互作用和严重肾功能不全时的用药限制。

要点

  • 移植前治疗HCV可使几乎所有患者的移植物免于再感染。
  • 部分候选者经治疗后可出现显著临床改善并可能被剔除等待名单。
  • 移植后可选择早期治疗或疾病复发时治疗,但需注意DAA与免疫抑制剂等药物的相互作用。

核心结论

  • 该共识声明为肝移植候选者和受者中HCV治疗决策提供支持,尤其针对困难临床情况。

研究设计与样本

  • 由ELITA制定共识声明,针对肝移植中尚未广泛解决的HCV治疗问题。

主要发现

  • 移植前治疗HCV可使几乎所有患者的移植物免于再感染。
  • 部分候选者经治疗后可出现显著临床改善并可能被剔除等待名单。
  • 移植后治疗可选择移植后早期或疾病复发时,后者为过去采用的方式。
  • 部分DAA因与免疫抑制剂等多种药物存在相互作用而使用受限。
  • 严重肾功能不全时应避免使用某些DAA。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of safe and highly effective direct-acting antiviral agents (DAAs) has had huge implications for the hepatitis C virus (HCV) transplant field, and changed our management of both patients on the waiting list and those with HCV graft re-infection after liver transplantation (LT). When treating HCV infection before LT, HCV re-infection of the graft can be prevented in nearly all patients. In addition, some candidates show a remarkable clinical improvement and may be delisted. Alternatively, HCV infection can be treated post-LT either soon after the transplant, taking advantage of the removal of the infected native liver, or at the time of disease recurrence, as was carried out in the past. In either case, some DAAs have a limited use because of their drug to drug interactions with various immunosuppressants as well as the many other drugs liver transplant recipients are often prescribed. In addition, some DAAs should be avoided in case of severe renal failure, which is not an unusual complication after LT. The present document provides a series of consensus statements on the LT issues that have not been extensively addressed previously. These statements have been developed to support physicians and other stakeholders in charge of LT candidates and recipients when deciding to treat HCV, especially in difficult situations.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017. PMID: 28323126. doi:10.1016/j.jhep.2017.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。